Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Blood-Based Biomarkers for Metabolic Syndrome
share announcement

Blood-Based Biomarkers for Metabolic Syndrome

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 3197

Special Issue Editor

Prof. Dr. Mina Hur

E-Mail Website
Guest Editor
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea
Interests: biomarker research; diagnostic hematology; transfusion medicine; molecular genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolic syndrome (MetS) is a pathologic condition characterized by abdominal obesity, insulin resistance, hypertension, and dyslipidemia. As a result of the global spread of the Western lifestyle, MetS has become one of the modern world’s major health hazards, and is prevalent in various ethnicities and geographical regions. This syndrome is a cluster of multi-dimensional cardiovascular (CV) risk factors, feeding into the spread of diseases such as type 2 diabetes, coronary diseases, stroke, as well as other disabilities. In addition to lifestyle modification, understanding lipid dynamics related to MetS and exploring related biomarkers has clinical significance regarding the refinement of atherosclerotic CV risk and MetS risk profiles.

Biomarkers are compounds that can be measured and evaluated as indicators of normal biological processes and pathogenic processes or in pharmacologic responses to a drug. A “biomarker” is any laboratory tool with the potential to detect and characterize diseases more easily, simplify complex clinical algorithms, and improve problem solving in clinical practice. An ideal biomarker should aid in early diagnosis, help with risk stratification, and be capable of monitoring the response to treatment and predicting outcomes. This Special Issue of Metabolites, “Blood-Based Biomarkers for Metabolic Syndrome”, will be dedicated to publishing translational and clinical research related to biomarker application in MetS. Potential topics include, but are not limited to: translational or clinical application of novel biomarkers, new application of conventional biomarkers or multi-marker approaches, and laboratory or technical issues for biomarker measurements. Other challenging and interesting issues dealing with current advances are also highly desired.

Prof. Dr. Mina Hur
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic syndrome
  • biomarker
  • clinical research
  • translational research
  • cardiovascular risk
  • abdominal obesity
  • insulin resistance
  • hypertension
  • dyslipidemia

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 989 KiB  
Article
Association of Serum Adiponectin Biomarker with Metabolic Syndrome Components in Koreans with Extremely High HDL Cholesterol Levels in General Health Checkup
by Hyun Suk Yang, Gun-Hyuk Lee, Donghwan Kim, Kyeong Ryong Lee and Mina Hur
Metabolites 2022, 12(11), 1086; https://doi.org/10.3390/metabo12111086 - 9 Nov 2022
Viewed by 940
Abstract
Adiponectin and high-density lipoprotein cholesterol (HDL-C) are negative predictors for cardio-metabolic disorders. This study explored adiponectin’s role in predicting multiple metabolic syndrome components (multi-MetSC) in subjects with extremely high HDL-C levels overall and by sex. We enrolled adults with extremely high HDL-C levels [...] Read more.
Adiponectin and high-density lipoprotein cholesterol (HDL-C) are negative predictors for cardio-metabolic disorders. This study explored adiponectin’s role in predicting multiple metabolic syndrome components (multi-MetSC) in subjects with extremely high HDL-C levels overall and by sex. We enrolled adults with extremely high HDL-C levels (≥90 mg/dL) in general health checkups and compared adiponectin levels in subjects with and without multi-MetSC. Among 274 subjects (median 44 years, female 79.6%), 19 (6.9%) had a multi-MetSC. The adiponectin level was significantly lower in subjects with multi-MetSC than without (females: 9.2 [6.2–13.3] vs. 12.0 [9.7–15.9] µg/mL, p = 0.039; males: 6.9 ± 2.4 vs. 10.0 ± 5.2 µg/mL, p = 0.013). The optimal cutoff values to predict multi-MetSC were 9.7 µg/mL (sensitivity 64%, specificity 74%) in females and 9.6 µg/mL (sensitivity 100%, specificity 44%) in males. Compared with the high adiponectin group, the low group revealed higher fasting glucose in females and higher waist circumference, visceral fat area, and HDL-C levels in males. Multiple logistic regression analysis confirmed adiponectin as an independent predictor of multi-MetSC (OR 0.85, 95% CI 0.71–0.97). Adiponectin could be a potential biomarker for multi-MetSC in general health checkup subjects with extremely high HDL-C levels. There were sex differences in the metabolic risk factors between low and high adiponectin groups. Full article
(This article belongs to the Special Issue Blood-Based Biomarkers for Metabolic Syndrome)
►▼ Show Figures

Figure 1

13 pages, 1545 KiB  
Article
Application of Mitochondrial and Oxidative Stress Biomarkers in the Evaluation of Neurocognitive Prognosis Following Acute Carbon Monoxide Poisoning
by Yong Sung Cha, Jae Seung Chang, Hyun Kim and Kyu-Sang Park
Metabolites 2022, 12(3), 201; https://doi.org/10.3390/metabo12030201 - 24 Feb 2022
Cited by 2 | Viewed by 1881
Abstract
Mitochondrial and oxidative stress play critical roles in the pathogenic mechanisms of carbon monoxide (CO)-induced toxicity. This study was designed to evaluate whether the serum levels of specific stress biomarkers might reflect brain injury and act as prognostic markers for the development of [...] Read more.
Mitochondrial and oxidative stress play critical roles in the pathogenic mechanisms of carbon monoxide (CO)-induced toxicity. This study was designed to evaluate whether the serum levels of specific stress biomarkers might reflect brain injury and act as prognostic markers for the development of neurocognitive sequelae following CO poisoning. We analyzed the data from 51 adult patients admitted with acute CO poisoning and measured the serum level expression of growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21), indicators of mitochondrial stress, and 8-Oxo-2′-deoxyguanosine (8-OHdG) and malondialdehyde (MDA), indicators of oxidative stress. Serum was collected upon arrival at the hospital, at 24 h post treatment, and within 7 days of HBO2 therapy. Global Deterioration Scale scores were measured 1 month post incident and used to place the patients in either favorable or poor outcome groups. Initial serum GDF15 and 8-OHdG concentrations were significantly increased in the poor-outcome group and all four biomarkers decreased at 24 h post HBO2 therapy, and were then maintained or further decreased at the 1-week mark. Notably, the degree of change in these biomarkers between baseline and 24 h post HBO2 were significantly larger in the poor-outcome group, reflecting greater CO-associated stress, confirming that post-CO poisoning serum biomarker levels and their response to HBO2 were proportional to the initial stress. We suggest that these biomarkers accurately reflect neuronal toxicity in response to CO poisoning, which is consistent with their activity in other pathologies. Full article
(This article belongs to the Special Issue Blood-Based Biomarkers for Metabolic Syndrome)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop